EP Patent

EP1628648A1 — Deramciclane-fumarate tablets

Assigned to Egis Pharmaceuticals PLC · Expires 2006-03-01 · 20y expired

What this patent protects

The invention relates to tablets comprising deramciclane-fumarate of the Formula (I) whereby said tablets contain (related to the total weight) more than 50 % by weight of deramciclane-fumarate, 5-20 % by weight of a binder, 5-20 % by weight of microcrystalline cellu­lose having …

USPTO Abstract

The invention relates to tablets comprising deramciclane-fumarate of the Formula (I) whereby said tablets contain (related to the total weight) more than 50 % by weight of deramciclane-fumarate, 5-20 % by weight of a binder, 5-20 % by weight of microcrystalline cellu­lose having an average particle size below 30 µm, 1-10 % by weight of a disintegrant, 0.5-4 % by weight of a lubricant, 0.5-4 % by weight of an anti-adhesive agent and 0-30 % by weight of a filler. Deramciclane-fumarate is a known anxiolytic active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
EP1628648A1
Jurisdiction
EP
Classification
—
Expires
2006-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Egis Pharmaceuticals PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.